Greenwich LifeSciences, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 7.83 million compared to USD 4.57 million a year ago. Basic loss per share from continuing operations was USD 0.61 compared to USD 0.35 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.85 USD | +3.85% | -0.27% | +41.16% |
01:47pm | Greenwich LifeSciences' CEO Acquires $2.5 Million in Shares | MT |
May. 20 | Greenwich LifeSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+41.16% | 191M | |
+0.85% | 92.4B | |
-3.16% | 38.08B | |
-9.63% | 34.05B | |
+73.38% | 27.77B | |
-12.63% | 16B | |
-0.16% | 14.1B | |
-9.38% | 11.91B | |
+172.59% | 10.37B | |
-49.44% | 10.2B |
- Stock Market
- Equities
- GLSI Stock
- News Greenwich LifeSciences, Inc.
- Greenwich LifeSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022